Vaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders
dc.contributor.author | Kaczmarek, Radoslaw | |
dc.contributor.author | El Ekiaby, Magdy | |
dc.contributor.author | Hart, Daniel P. | |
dc.contributor.author | Hermans, Cedric | |
dc.contributor.author | Makris, Mike | |
dc.contributor.author | Noone, Declan | |
dc.contributor.author | O’mahony, Brian | |
dc.contributor.author | Page, David | |
dc.contributor.author | Peyvandi, Flora | |
dc.contributor.author | Pipe, Steven W. | |
dc.contributor.author | Sannié, Thomas | |
dc.contributor.author | Schlenkrich, Uwe | |
dc.contributor.author | Skinner, Mark W. | |
dc.contributor.author | Srivastava, Alok | |
dc.contributor.author | Bok, Amanda | |
dc.contributor.author | Pierce, Glenn F. | |
dc.date.accessioned | 2021-08-03T18:15:56Z | |
dc.date.available | 2022-08-03 14:15:55 | en |
dc.date.available | 2021-08-03T18:15:56Z | |
dc.date.issued | 2021-07 | |
dc.identifier.citation | Kaczmarek, Radoslaw; El Ekiaby, Magdy; Hart, Daniel P.; Hermans, Cedric; Makris, Mike; Noone, Declan; O’mahony, Brian ; Page, David; Peyvandi, Flora; Pipe, Steven W.; Sannié, Thomas ; Schlenkrich, Uwe; Skinner, Mark W.; Srivastava, Alok; Bok, Amanda; Pierce, Glenn F. (2021). "Vaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders." Haemophilia (4): 515-518. | |
dc.identifier.issn | 1351-8216 | |
dc.identifier.issn | 1365-2516 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/168487 | |
dc.publisher | BioNTech | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Vaccination against COVID- 19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168487/1/hae14271.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168487/2/hae14271_am.pdf | |
dc.identifier.doi | 10.1111/hae.14271 | |
dc.identifier.source | Haemophilia | |
dc.identifier.citedreference | Chakraborty R, Parvez S. COVID- 19: an overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol. 2020; 180: 114184. | |
dc.identifier.citedreference | Verbeke R, Lentacker I, De Smedt SC, et al. Three decades of messenger RNA vaccine development. Nano Today. 2019; 28: 100766. | |
dc.identifier.citedreference | Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV- 19 vaccine (AZD1222) against SARS- CoV- 2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2020. | |
dc.identifier.citedreference | Pipe SW, Kaczmarek R, Srivastava A, et al. Management of COVID- 19- associated coagulopathy in persons with haemophilia. Haemophilia. 2020. | |
dc.identifier.citedreference | Hermans C, Lambert C, Sogorb A, et al. In- hospital management of persons with haemophilia and COVID- 19: practical guidance. Haemophilia. 2020; 26 ( 5 ): 768 - 772. | |
dc.identifier.citedreference | Moderna- s COVID- 19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. https://investors.modernatx.com/news- releases/news- release- details/modernas- covid- 19- vaccine- candidate- meets- i | |
dc.identifier.citedreference | Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID- 19 vaccine. N Engl J Med. 2020;NEJMoa2034577. | |
dc.identifier.citedreference | Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS- CoV- 2 mRNA- 1273 vaccine in older adults. N Engl J Med. 2020; 383: 2427 - 2438. | |
dc.identifier.citedreference | Confirmation of guidance to vaccination centres on managing allergic reactions following COVID- 19 vaccination with the Pfizer/BioNTech vaccine. https://www.gov.uk/government/news/confirmation- of- guidance- to- vaccination- centres- on- managing- allergic- reactio | |
dc.identifier.citedreference | Lai JD, Moorehead PC, Sponagle K, et al. Concurrent influenza vaccination reduces anti- FVIII antibody responses in murine hemophilia A. Blood. 2016; 127 ( 26 ): 3439 - 3449. | |
dc.identifier.citedreference | Platokouki H, Fischer K, Gouw SC, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 2018; 24 ( 2 ): 283 - 290. | |
dc.identifier.citedreference | Garvey LH, Nasser S. Allergic reactions to the first COVID- 19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2020. | |
dc.identifier.citedreference | COVID- 19 MRNA Vaccine BNT162b2 Concentrate for Solution for Injection [Package Insert]. Mainz, Germany: BioNTech; 2020. | |
dc.identifier.citedreference | Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices- Interim Recommendation for Use of Pfizer- BioNTech COVID- 19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 ( 50 ): 1922. | |
dc.identifier.citedreference | MASAC Document 221. Recommendations on Administration of Vaccines to Individuals with Bleeding Disorders | National Hemophilia Foundation. https://www.hemophilia.org/healthcare- professionals/guidelines- on- care/masac- documents/masac- document- 221- recommend | |
dc.identifier.citedreference | Srivastava A, Brewer AK, Mauser- Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013; 19 ( 1 ): e1 - 47. | |
dc.identifier.citedreference | Santagostino E, Riva A, Cesaro S, et al. Consensus statements on vaccination in patients with haemophilia- results from the Italian haemophilia and vaccinations (HEVA) project. Haemophilia. 2019; 25 ( 4 ): 656 - 667. | |
dc.identifier.citedreference | Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020; 26 ( S6 ): 1 - 158. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.